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Antibodies that immunoprecipitate
125I-a-dendrotoxin-labelled voltage-gated potassium channels extracted from mammalian
brain tissue have been identiﬁed in patients with neuromyotonia, Morvan’s syndrome, limbic encephalitis and a few cases of
adult-onset epilepsy. These conditions often improve following immunomodulatory therapies. However, the proportions of the
different syndromes, the numbers with associated tumours and the relationships with potassium channel subunit antibody
speciﬁcities have been unclear. We documented the clinical phenotype and tumour associations in 96 potassium channel
antibody positive patients (titres 4400pM). Five had thymomas and one had an endometrial adenocarcinoma. To deﬁne the
antibody speciﬁcities, we looked for binding of serum antibodies and their effects on potassium channel currents using human
embryonic kidney cells expressing the potassium channel subunits. Surprisingly, only three of the patients had antibodies
directed against the potassium channel subunits. By contrast, we found antibodies to three proteins that are complexed with
125I-a-dendrotoxin-labelled potassium channels in brain extracts: (i) contactin-associated protein-2 that is localized at the
juxtaparanodes in myelinated axons; (ii) leucine-rich, glioma inactivated 1 protein that is most strongly expressed in the
hippocampus; and (iii) Tag-1/contactin-2 that associates with contactin-associated protein-2. Antibodies to Kv1 subunits
were found in three sera, to contactin-associated protein-2 in 19 sera, to leucine-rich, glioma inactivated 1 protein in
55 sera and to contactin-2 in ﬁve sera, four of which were also positive for the other antibodies. The remaining 18 sera
were negative for potassium channel subunits and associated proteins by the methods employed. Of the 19 patients with
contactin-associated protein-antibody-2, 10 had neuromyotonia or Morvan’s syndrome, compared with only 3 of the 55
leucine-rich, glioma inactivated 1 protein-antibody positive patients (P50.0001), who predominantly had limbic encephalitis.
The responses to immunomodulatory therapies, deﬁned by changes in modiﬁed Rankin scores, were good except in the patients
with tumours, who all had contactin-associated-2 protein antibodies. This study conﬁrms that the majority of patients with high
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protein and contactin-associated protein-2 as the major targets of potassium channel antibodies, and their associations with
different clinical features, begins to explain the diversity of these syndromes; furthermore, detection of contactin-associated
protein-2 antibodies should help identify the risk of an underlying tumour and a poor prognosis in future patients.
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125I--DTX = iodinated
alpha-dendrotoxin; IgG = immunoglobulin G; Lgi1 = leucine-rich, glioma inactivated 1 protein; VGKC = voltage-gated potassium
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Introduction
Voltage-gated potassium channel (VGKC) antibodies have been
reported in association with three main clinical syndromes: neuro-
myotonia, Morvan’s syndrome and limbic encephalitis (for review
see Vincent, 2008). Neuromyotonia is a peripheral nerve hyper-
excitability syndrome characterized by muscle cramps and stiffness
(Hart et al., 2001). In Morvan’s syndrome, symptoms of neuro-
myotonia are associated with autonomic and central nervous
system dysfunction, with frequent insomnia (Liguori et al., 2001;
Josephs et al., 2004). By contrast, limbic encephalitis is character-
ized by amnesia, confusion, seizures and personality change or
psychosis, with discrete hippocampal abnormalities on brain MRI,
and in patients with VGKC-antibodies there is often an associated
hyponatraemia (Vincent et al., 2004; Graus et al., 2008). In add-
ition to these syndromes, VGKC-antibodies have also been identi-
ﬁed in some patients with idiopathic epilepsy (McKnight et al.,
2005) and recently in a form of late-onset dystonic epilepsy
(Irani et al., 2008; Barajas et al., 2009). In most cases these syn-
dromes have a subacute onset and respond well to immunomo-
dulatory therapies (Buckley et al., 2001; Thieben et al., 2004;
Vincent et al., 2004; Geschwind et al., 2008; Irani et al., 2008),
although neuromyotonia may require only symptomatic treat-
ments. Both neuromyotonia and Morvan’s syndrome can be asso-
ciated with tumours, particularly thymomas, but tumours appear
to be uncommon in typical VGKC-antibody associated limbic
encephalitis or idiopathic epilepsy. However, there have been no
systematic studies of large cohorts, except one where the clinical
syndromes were not deﬁned (Tan et al., 2008).
VGKC-antibodies are usually detected by immunoprecipitation
of iodinated -dendrotoxin (
125I--DTX)-labelled VGKCs in
digitonin-solubilized mammalian brain homogenates (Shillito
et al., 1995; Hart et al., 1997; Thieben et al., 2004). The
VGKC-antibody titres tend to be higher (4400pM; normal
5100pM) in patients with CNS conditions compared to those
with isolated neuromyotonia (generally between 100 and
1000pM). -DTX binds with high afﬁnity to three different
VGKC subunits, Kv1.1, 1.2 and 1.6. In neuromyotonia, early stu-
dies suggested that the antibodies were variably directed against
these three Kv1 subunits (Hart et al., 1997), and the pathogenic
role of puriﬁed Immunoglobulin G (IgG) was demonstrated by
passive transfer to mice (Sinha et al., 1991; Shillito et al., 1995),
and by application to neuronal cell line cultures or Kv1-transfected
cells in vitro (Shillito et al., 1995; Nagado et al., 1999; Tomimitsu
et al., 2004). In limbic encephalitis, immunohistological studies
suggested antibodies mainly to Kv1.1 (Kleopa et al., 2006).
Our main aim was to investigate the speciﬁcity of the
VGKC-antibodies for the different Kv1 subtypes and to relate
these to the clinical phenotypes. In doing so, we also wished to
describe the clinical phenotypes, tumour associations and treat-
ment responses in the different syndromes. Surprisingly, only a
few patients had antibodies binding to the Kv1 subunits them-
selves but most bound only to one of two proteins, leucine-rich
glioma inactivated 1 (Lgi1) or contactin-associated protein-2
(Caspr2), that are part of the DTX-labelled VGKC complexes
used in the serological assay. Preliminary results have been
reported in abstracts (Vincent, 2009; Irani et al., 2010). Five
sera bound to contactin-2 itself but four of these sera also
bound to Kv1, Caspr2 or Lgi1.
Materials and methods
Clinical material
Serum samples were stored at  20 C. The study was approved by the
Oxfordshire Research Ethics Committee A (07/Q160X/28). To explore
the antibody speciﬁcities, we initially used sera from patients with
well-deﬁned clinical syndromes (as previously described in Liguori
et al., 2001; Vincent et al., 2004). Subsequently, to study the clinical
phenotypes in a large cohort, we sent consent forms and question-
naires to neurologists, identiﬁed on the request forms, who had sent
sera that were positive for VGKC-antibodies at4400pM (high VGKC-
antibodies) and that were representative of those received during the
period 2003–08. To assess the effects of treatments, we asked the
neurologists to provide modiﬁed Rankin scores (Graus et al., 2001)
at onset and latest follow-up. From completed questionnaires and/or
clinic letters, visits (S.R.I.) and/or telephone conversations, the clinical
data were obtained for 96 patients.
Plasmid constructs
The cDNAs represented the human sequences, except for the
b2, which was rat. cDNAs encoding full-length human Kv1.1, 1.2,
1.6 and rat b2 subunits (as in Kleopa et al., 2006) were cloned into
pcDNA3.1-hygro (Invitrogen Ltd, CA, USA). The full-length human
MuSK-EGFP construct has been described previously (Leite et al.,
2008). Lgi1 was ampliﬁed by polymerase chain reaction from an
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digested with Nhe1/Xho1 and subcloned into pcDNA 3.1 (+)
(Invitrogen, UK). The vector pCR4-TOPO that contained the cDNA
for Caspr2 (IMAGE: 7939625 from Geneservice) was digested with
EcoRI. The fragment was subcloned into pcDNA3.1 (+) (Invitrogen)
to give an untagged Caspr2 that expressed in mammalian cells. In
order to tag Caspr2 with enhanced green ﬂuorescent protein (EGFP),
the pcDNA3.1 (+)-Caspr2 plasmid was digested with XhoI and XmaI.
The fragment was subcloned into pEGFP-N1 (Clontech Laboratories,
CA, USA). To express Lgi1 fused to the transmembrane region of
Caspr2, the C-terminal cDNA sequence of Caspr2 (residues
1248–1331) was ampliﬁed by polymerase chain reaction with the pri-
mers GATCCTCGAGGGACAAGGCCAAGCTATAAGAAATG and ATCG
TTTAAACTCAAATGAGCCATTCCTTTTTGC. This was cloned in frame
with Lgi1 in pcDNA3.1+ with the restriction enzymes XhoI/PmeI. The
stop codon was removed by site directed mutagenesis using the pri-
mers GTTGACTTAAGCGCAGGACTCGAGGGACAAGG and CCTTGTC
CCTCGAGTCCTGCGCTTAAGTCAAC, to give a ﬁnal product of Lgi1
attached to the transmembrane and cytoplasmic domains (residues
1248–1331) of Caspr2.
Transfection of human embryonic
kidney cells
Human embryonic kidney 293 (HEK293) cells were cultured in
Dulbecco’s modiﬁed Eagle’s medium supplemented with 10% foetal
calf serum (TCS Cellworks Ltd, Buckingham, UK) and 100 units/ml
each of penicillin G and streptomycin (Invitrogen) at 37 Ci na5 %
CO2 atmosphere. Cells were grown on six-well culture plates for
immunoadsorption and toxin binding experiments, on 13mm glass
coverslips placed in six-well cell culture plates for microscopy, and in
175cm
2 ﬂasks for protein extraction. Using polyethylenimine, cells
were transiently co-transfected with plasmids containing Kv1.1, 1.2
and 1.6, EGFP, MuSK-EGFP, Caspr2-EGFP, Lgi1, contactin-2 cDNA
(kind gift of Dr Karagogeos, University of Crete, Greece) or Lgi1
fused to Caspr2.
Electrophysiological studies on human
embryonic kidney cells
For measuring VGKC currents, the HEK293 cells were co-transfected
with Kv1.1 and EGFP, or Kv1.6 and EGFP, and plated onto glass
coverslips for whole-cell patch clamp recordings (see Supplementary
Methods for the details). The effects of patient plasmas on Kv1
currents were determined after acute application, or after incubation
for 24 or 72h.
Binding of antibodies to transfected
human embryonic kidney cells
Forty-eight hours after transfection, the immunoﬂuorescent staining
of the cells was performed. The coverslips were transferred to individ-
ual wells in 24-well culture plates and incubated at room temperature
for 45min with mouse anti-Kv1.1 extracellular domain antibody (1:100,
Neuromab, California) or patient serum (1:20–1:100, as speciﬁed);
these were diluted in Dulbecco’s modiﬁed Eagle’s medium buffered
with HEPES [N-(2-hydroxyethyl)piperazine-N0-(2-ethanesulphonic
acid)] with added 1% bovine serum albumin to block non-speciﬁc bind-
ing. The cells were subsequently washed three times in Dulbecco’s
modiﬁed Eagle’s medium/HEPES buffer and ﬁxed with 3%
formaldehyde in phosphate buffered saline at room temperature for
15min, followed by further washing. They were then labelled for
45min at room temperature with anti-mouse IgG or anti-human IgG
Alexa Fluor 568-conjugated secondary antibody (Invitrogen-Molecular
probes, Paisley, UK) at 1:750 in 1% bovine serum albumin/Dulbecco’s
modiﬁed Eagle’s medium/HEPES buffer. For cell permeabilization, cells
were initially incubated with ﬁxative (as above) and subsequently all
solutions contained 0.1% Triton-X-100. Rabbit anti-Kv1.1/1.2 and
1.6 antibodies (1:500, Alamone, Israel) were visualized with an
anti-rabbit IgG Alexa Fluor 568-conjugated secondary antibody
(Invitrogen-Molecular probes) on permeabilised cells. All coverslips
were subsequently washed three times in phosphate buffered saline
and mounted on slides in ﬂuorescent mounting medium
(DakoCytomation, Cambridge, UK) with DAPI (40,60-diamidino-2-
phenlindoledichloride, 1:1000). They were visualized using a ﬂuores-
cence microscope with a MacProbe v4.3 digital imaging system.
Immunoprecipitation assays for VGKCs,
Kv1 subunits and Caspr2
This was performed as described earlier (Hart et al., 1997). VGKC
complexes were extracted from rabbit brain membranes solubilized
in 2% digitonin (Calbiochem, USA) in DTX-buffer (100mM NaCl,
20mM Tris, 5mM KCl adjusted to pH 7.12) at 37 C for 20min.
The supernatant was diluted 1:2 with PTX (0.02M phosphate buffer
and 0.1% Triton-X-100, pH 7.2) and incubated with 10
6cpm/ml of
125I--DTX (Perkin Elmer, USA). An amount of 50ml volumes of the
125I--DTX-labelled extracts were incubated with 5 and 1ml of each
serum, the IgG-VGKC complexes were precipitated with anti-human
IgG (The Binding Site, UK), and the pellets were washed and counted
on a gamma counter (Cobra2, Perkin Elmer, USA).
To immunoprecipitate
125I--DTX-labelled Kv1s, cells were trans-
fected with the cDNAs for the different subunits as above. At 48h
post-transfection, conﬂuent 175cm
2 ﬂasks of transfected cells were
washed with phosphate buffered saline and lysed in 2% digitonin in
DTX-buffer, with 1:100 protease inhibitor cocktail (Sigma-Aldrich, UK).
Lysates were rotated for 1h, spun (13000rpm for 5min at 4 C) and
labelled with
125I--DTX as above. An amount of 5ml of human sera
or commercial antibodies to Kv1.1, 1.2, 1.6 (Alomone Labs, USA)
were added and the precipitations performed with goat anti-human
IgG (RSR Ltd UK; we ﬁnd that this antiserum can be used to immu-
noprecipitate human, mouse and rabbit IgG). The pellets were counted
as above.
For immunoprecipitation of Caspr2, ﬂasks of EGFP-Caspr2-
transfected HEK293 cells were treated similarly and aliquots of the
supernatant containing 100fU of EGFP-Caspr2 were tested with 5
or 1ml of each serum. The complexes were immunoprecipitated with
Protein A beads. For counting of the EGFP, the pellets were resus-
pended in 200ml, transferred to a 96-well plate and analysed on a
ﬂuorescent plate reader (Gemini XS, Molecular Probes).
Indirect immunoﬂuorescence on mouse
tissue and live rat hippocampal neurons
Immunoﬂuorescence detection of antibodies binding to ﬁxed
mouse cerebral and cerebellar sections, and sciatic nerve teased
ﬁbres was performed as described previously (Kleopa et al., 2006).
Details on tissues and binding of the serum antibodies to live neurons
in culture are provided in the Supplementary Methods and in Irani
et al. (2010).
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VGKC-antibodies and clinical features
in the large cohort
We obtained clinical information on 96 individuals who had not
previously been studied and whose samples were representative of
the4500 high VGKC-antibody positive sera identiﬁed since 2004.
The majority were from the UK, with 14 from other European
countries. The clinical features are summarized in Table 1. All of
the 64 patients deﬁned as limbic encephalitis (Bien and Elger,
2007) had amnesia and/or confusion and 59 (92%) had seizures,
but only 40 (62%) had medial temporal lobe inﬂammation on MRI
and only 38 (59%) had hyponatraemia, which has often been
identiﬁed in VGKC-antibody associated limbic encephalitis
(Vincent et al., 2004; Graus et al., 2008). All ﬁve patients with
Morvan’s syndrome were male and had clinical neuromyotonia,
conﬁrmed on EMG, with dysautonomia, pain, usually in the feet
and often burning in nature, and marked insomnia.
The distinction between the syndromes was not absolute. A
third of the patients with limbic encephalitis had sleep disorders,
including six with insomnia, which are more typically associated
with Morvan’s syndrome. Four of the patients with neuromyoto-
nia had pain or dysautonomia but they had no CNS involvement
and were generally less severely affected than the patients with
Morvan’s syndrome; we used the diagnosis of neuromyotonia
provided by the neurologists. Four patients had epilepsy only
and twelve patients had presentations that could not be deﬁned
as limbic encephalitis, Morvan’s syndrome, neuromyotonia or epi-
lepsy (summarized in Supplementary Table 1).
Nine patients had past histories of various malignancies, includ-
ing two prostate, one breast, one non-small cell lung cancer and
one melanoma, but all of these appeared to be inactive or stable
for 45 years. Active tumours were present in only six of the
patients; ﬁve thymomas and one endometrial adenocarcinoma.
Four patients had a history of myasthenia gravis (one with
limbic encephalitis who subsequently also developed neuromyoto-
nia and neuromyelitis optica, one with Morvan’s syndrome, two
with neuromyotonia).
Most VGKC-antibodies bind to
associated VGKC-complex proteins
and not directly to Kv1 subunits
Figure 1A shows the VGKC-antibody titres in the 96 patients. To
deﬁne the antibody targets, we expressed the individual -DTX-
binding Kv1 subunits (Kv1.1, 1.2 and 1.6) in HEK293 cells, and
compared binding of patients’ serum IgG antibodies with that of
commercial polyclonal antibodies to the individual subunits. For
these studies we used sera from previously characterized patients
with known limbic encephalitis or Morvan’s syndrome (VGKC-
antibodies 4400pM). Although commercial Kv1.1 antibodies, for
instance, bound to the Kv1.1-transfected cells, none of the pa-
tients’ IgG showed detectable binding (e.g. Fig. 1B). In addition,
we measured voltage-dependent currents in Kv1.1- and Kv1.6-
transfected HEK293 cells. As expected, there was a marked reduc-
tion in Kv1 currents with the speciﬁc VGKC blocker -DTX
(Fig. 1C), but no effect following application of VGKC-antibody
positive sera, either acutely (Fig. 1D) or after 24 or 72h of
Table 1 Clinical features in 96 patients with VGKC-antibodies4400pM
Limbic encephalitis
(n=64)
Morvan’s
syndrome (n=5)
Neuromyotonia
(n=11)
Epilepsy
(n=4)
Other disorders
(n=12)
Age at onset, median (range) 63 (19–83) 64 (58–69) 54 (39–74) 65 (51–70) 45 (17–83)
Male:female 44:20 5:0 7:4 3:1 9:3
Amnesia 64 5 0 0 7
Confusion/disorientation 64 5 0 0 8
Seizures 59 3 0 4 2
MRI medial temporal lobe
high signal on T2 or FLAIR
40 0 ND 0 0
Movement disorder 1 dyskinesia; 2 myoclonus 0 0 0 2
Hyponatraemia 38 2 0 0 0
Active tumour 0 1 5 0 0
Sleep disorder 8 hypersomnia; 6 insomnia;
4 REMSBD; 3 sleep reversal
5 insomnia 1 insomnia 0 2
Ataxia 6 0 1 1 0
Pain 3 5 4 0 1
Hyperhidrosis 6 2 4 0 0
Any dysautonomia 7 4 4 0 2
Neuromyotonic discharges 0 5 11 0 0
Myasthenia gravis 1 1 2 0 0
Other features 1 peripheral neuropathy 4 peripheral
neuropathies
0 See Supplementary
Table 1
ND=not determined; REMSBD=rapid eye movement sleep behaviour disorder.
Lgi1 and Caspr2 are targets for VGKC antibodies Brain 2010: 133; 2734–2748 | 2737Figure 1 VGKC-antibodies immunoprecipitate VGKCs from brain extracts but do not bind directly to Kv1 subunits. (A) VGKC-antibody
levels (pM), measured by immunoprecipitation of
125I--DTX-VGKCs from rabbit brain extracts, in 96 patients, divided according to the
clinical diagnoses (Table 1), and from 70 healthy or other disease controls. The cut-off (100pM) represents the mean plus three standard
deviations of the healthy control values. (B) Binding of antibodies to the surface of HEK293 cells transfected with cDNA for the Kv1.1
subunit; the cells were co-transfected with EGFP to identify those cells taking up the cDNA. Positive staining was found with a rabbit
antibody raised against the extracellular domain of Kv1.1 (anti-Kv1.1), but VGKC-antibody positive sera did not show any staining (lower
panels). Magniﬁcation 1000 (C) Voltage-dependent currents measured in Kv1.1 transfected HEK293 cells were substantially reduced by
the neurotoxin, -DTX (1mM). (D) Sera (1:100 diluted) from six healthy individuals (total 17 cells recorded) or from three individual
patients with VGKC-antibodies (n=number of cells examined for each patient) had no effect on voltage-dependent currents in Kv1.1
transfected HEK293 cells (Table 2). Ab=antibody; HC=healthy control.
Table 2 Summary of effects of VGKC-antibody positive patients’ plasma antibodies on a-DTX-sensitive currents
Peak current
amplitude (pA)
in incubation
medium alone
+1mm a-DTX
percentage of
medium alone
(number of recordings)
Duration of
incubation in
plasma (1:100)
Current amplitudes
from recordings
in six healthy
individuals’ plasmas
(number of recordings)
a
Current amplitude
averaged from recordings
in VGKC-antibody patients’
plasmas, as percentage of controls
(number of recordings)
a
Kv1.1 3286 211 (73) 37 6% (4) Acute incubation 103 4% (17) 98.6 1% (15)
ND 24h 100 12.7% (45) 97 10% (55)
ND 72h 100 13 % (34) 127 18% (43)
Kv1.6 9594 898 (18) 9 1% (3) Acute 101 3% (17) 95.8 3% (14)
ND 24h 100 11% (29) 103 11% (39)
ND 72h 100 8% (47) 92 13% (92)
a Results are presented as mean SEMs of the pretreatment amplitudes for the acute incubations, or of the mean of the healthy plasma recordings for the 24 and 72h
incubations; ND=not determined.
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summarized in Table 2).
Finally, to reproduce the immunoassays used for testing the
patients’ sera, which use
125I--DTX-labelled digitonin extracts of
rabbit brain tissue, we expressed Kv1.1, 1.2, 1.6 and b2 subunits
together in HEK293 cells, made a 2% digitonin extract, added
50000cpm of
125I--DTX to each 50ml aliquot, and compared
immunoprecipitations by the commercial antibodies to the individ-
ual subunits with that by the patients’ serum antibodies. All three
Kv1 subunits were well expressed and bound by their respective
antibodies, but only three of the VGKC-antibody positive sera
immunoprecipitated the
125I--DTX -labelled VGKCs (Fig. 2A).
From these results, we concluded that the majority of VGKC-
antibody sera did not bind directly to Kv1 subunits but might bind
to non-Kv1 proteins that remain complexed with the Kv1s in the
rabbit brain digitonin extracts; digitonin is a mild detergent that
does not dissociate all protein complexes. To see whether we
could dissociate the sites for the patients’ antibodies from the
Kv1s, we added increasing amounts of the harsh detergent
sodium dodecyl sulphate to the
125I--DTX-labelled VGKCs in
rabbit brain extracts (Fig. 2B). Immunoprecipitation of VGKCs
by the patients’ antibodies was sensitive to low concentrations
(e.g. 0.025%) of sodium dodecyl sulphate, which do not usually
affect the binding of antibodies directly to their targets (e.g. anti-
bodies to acetylcholine receptors or MuSK in myasthenia, unpub-
lished results), whereas the commercial antibodies to Kv1.1 or 1.2,
as expected, were able to immunoprecipitate the
125I--DTX -
labelled VGKCs at these sodium dodecyl sulphate concentrations
(Fig. 2B).
We then tested the brain extract with commercial antibodies
directed against proteins reported to associate with Kv1s: Lgi1,
Caspr2 and contactin-2 (Poliak et al., 1999, 2003; Schulte et al.,
2006). The antibodies to these proteins precipitated approximately
60, 20 and  5% of the total number of
125I--DTX-binding sites
Figure 2 VGKCs are not the targets for the VGKC-antibodies. (A) A digitonin-extract was prepared of HEK293 cells that had been
cotransfected with cDNAs for Kv1.1, 1.2, 1.6 and b2. The extract was labelled with
125I--DTX. Rabbit antibodies to each of the
Kv1 subunits, but only three of the 96 VGKC-antibody positive sera, immunoprecipitated the
125I--DTX-labelled Kv1 complexes,
showing that 93/96 of the patients’ antibodies did not bind the Kv1s at detectable levels. (B) The effect of a harsher detergent on
VGKC-complexes. Addition of increasing amounts of sodium dodecyl sulphate showed that immunoprecipitation by the patients’
antibodies was reduced at very low concentrations of sodium dodecyl sulphate, in comparison with immunoprecipitation by the
antibodies to Kv1.1 or 1.2, suggesting that the patients’ binding sites were easily dissociated from the
125I--DTX-labelled Kv1s.
(C) Immunoprecipitation of
125I--DTX-labelled VGKCs extracted from brain tissue with antibodies directed against individual Kv1
subunits, Lgi1, Caspr2 and contactin-2. Each of the antibodies immunoprecipitated signiﬁcant but variable quantities of
125I--DTX
labelled rabbit brain Kv1s indicating that Lgi1, Caspr2 and contactin-2 were complexed with the Kv1s. SDS=sodium dodecyl sulphate.
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such as PSD95, PSD93 and ADAM22 did not precipitate appre-
ciable amounts of the
125I--DTX -VGKCs (data not shown).
Caspr2 is a target for VGKC-antibodies
Caspr2 co-localizes with Kv1.1 and 1.2 at neural juxtaparanodes,
is essential for VGKC clustering in vivo (Poliak et al., 2003), and
has a large extracellular sequence. In order to detect antibodies to
Caspr2, we expressed full-length human Caspr2 in HEK293 cells,
tagging the protein by introducing EGFP at the intracellular
C-terminus. Nineteen of the VGKC-antibody positive sera (20%)
at 1:100 dilution bound to the surface of these cells, and not to
cells transfected with control vectors (data not shown); control
sera did not bind Caspr2-transfected HEK293 cells (Fig. 3A). The
advantage of using EGFP-tagged Caspr2 is that the EGFP can be
used to quantify the antibodies after immunoprecipitation from
extracts of the transfected cells (Fig. 3B). There was a strong
positive correlation between VGKC-antibody titre and Caspr2-
EGFP-antibody titre (Fig. 3C), and immunoabsorption against
Caspr2-transfected cells, but not Kv1-transfected cells, abolished
precipitation of
125I--DTX-VGKCs (Supplementary Fig. 1A).
Caspr2 positive sera also bound strongly in a punctate manner
to the surface of cultured hippocampal neurons (Fig. 3D).
Lgi1 is a target for VGKC-antibodies
Lgi1 associates speciﬁcally with Kv1.1 subunits in CNS presynaptic
terminals (Schulte et al., 2006), and is a secreted protein that can
associate with neuronal and non-neuronal cell membranes (Sireol-
Piquer et al., 2006). To determine whether VGKC-antibodies
bound to Lgi1, we expressed full-length Lgi1 in HEK293 cells.
We found that 46 of the 96 VGKC-antibody positive sera
(48%), and none of 100 disease or healthy control sera, bound
to the surface of unpermeabilized Lgi1-transfected cells (Fig. 4A).
However, these sera also bound to cells in the same cultures that
Figure 3 Caspr2-antibodies in VGKC-antibody positive patients. (A) HEK293 cells were transfected with Caspr2-EGFP. A VGKC-antibody
positive serum (1:100) bound to the surface of the Caspr2-EGFP-expressing cells (green), whereas healthy serum (HC) did not bind.
Strong binding (red) was found in 19 of the 96 VGKC-antibody positive sera. (B) Immunoprecipitation of Caspr2-EGFP from digitonin
extracts of the transfected cells by 5ml of serum was also positive in 19 of the 96 sera, compared with sera from other neurological disease
controls (OND; multiple sclerosis, myasthenia with thymomas, non-VGKC-antibody associated encephalopathies) or healthy individuals
(controls). (C) There was a highly positive correlation between the binding to Caspr2-EGFP and binding to
125I--DTX-labelled Kv1s.
For these data, the Caspr2-EGFP immunoprecipitation was performed with 1ml of each serum to obtain more quantitative results.
(D) Caspr2-antibody positive serum IgGs (detected with ﬂuorescein-anti-human IgG, green) also bound strongly to the surface of live
cultured hippocampal neurons, 18 days in culture; the neurons were subsequently ﬁxed, permeabilized and stained for MAP2 (red).
The bar represents 25mm.
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cultures that were transfected with other vectors including
Kv1s, Caspr2 or a neuromuscular junction antigen, MuSK
(data not shown). Binding to the non-transfected cells was
explained by the fact that Lgi1 could be detected in the
medium of Lgi1-transfected cells (data not shown), consistent
with its reported secretion (Fukata et al., 2006; Sireol-Piquer
et al., 2006; Zhou et al., 2009) and this medium, but not
that from other HEK293 supernatants, could transfer to untrans-
fected HEK293 cells the ability to bind VGKC-antibodies
(Supplementary Fig. 3).
To conﬁrm that the Lgi1 binding was related to VGKC-
antibodies, as deﬁned by immunoprecipitation of
125I--DTX-VGKCs, we showed that immunoabsorption against
Lgi1-transfected cell cultures substantially reduced the ability
of sera to precipitate
125I--DTX-VGKCs from the rabbit brain
extract, whereas immunoabsorption against cells expressing
Kv1.1/1.2/1.6 did not (Fig. 4B). Sera with Lgi1 antibodies bound
to the surface of cultured hippocampal neurons (Fig. 4C),
although the binding was relatively weak. Finally, we established
a direct assay for Lgi1 antibodies by expressing Lgi1 fused on to
the C terminal/transmembrane domain of Caspr2 so that it
was anchored to the membrane. Lgi1-antibody positive sera
bound directly to the surface of the transfected cells (Fig. 4D),
and using this improved assay we were able to detect
Lgi1-antibodies in a further nine sera, making a total of 55 Lgi1-
antibody positives (57% overall).
Contactin-2 is a target for
VGKC-antibodies
Only ﬁve patients had antibodies to contactin-2 (Supplementary
Fig. 2). Two were also Caspr2-antibody positive. Of the other
three, one had Lgi1-antibodies, one had Kv1.2 antibodies and
one had no other VGKC-complex antibody detected.
Figure 4 Lgi1-antibodies are present in many VGKC-antibody positive patients. (A) HEK293 cells were co-transfected with cDNAs for
Lgi1 and EGFP (green) and incubated with patient sera (1:20). A representative image of binding of a limbic encephalitis VGKC-antibody
positive serum to the cells, detected with anti-human IgG (red). Note that the red stain is found not only on the Lgi1/EGFP transfected
cells, but also on the surface of non-transfected cells. Similar results were found in 46 of the 96 patient sera, but were not observed with
healthy control sera (HC). (B) Immunoadsorption of the VGKC-antibody positive sera against Lgi1-transfected cells, but not
against Kv1-transfected cells, substantially reduced immunoprecipitation of
125I--DTX–VGKC complexes from rabbit brain extracts.
(C) Lgi1-positive sera binding to a live hippocampal neuron detected with ﬂuorescein-anti-human IgG (green); the neurons were
subsequently ﬁxed, permeabilized and stained for MAP2 (red). The bar represents 25mm. (D) To conﬁrm that Lgi1 was the target for
the antibody binding shown in A, cDNA for Lgi1 was fused to cDNA for the transmembrane domain and cytoplasmic tail of Caspr2.
This construct expressed well in HEK293 cells and provided a direct assay for Lgi1 antibodies. Nine additional sera (one illustrated here)
bound to these cells; but there was no binding of healthy control sera or Caspr2-antibody positive sera.
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localization to their respective
antigens in mouse brain tissue
To explore further the relationships between the two main anti-
body targets, the potassium channels and the clinical syndromes,
we ﬁrst examined the relative distribution of Lgi1, Caspr2 and
Kv1.1 in the hippocampus and cerebellum of mouse brains. Lgi1
was expressed strongly in the mossy ﬁbre layer of the
CA3-hippocampal subﬁeld (Fig. 5B) as well as in the cerebellar
pinceau (Fig. 5D), in a manner similar to Kv1.1 (Fig. 5A and C).
By contrast, Caspr2 was expressed more prominently in the stra-
tum radiatum of CA3 (Fig. 5A and B) and molecular and granule
cell layers of the cerebellum (Fig. 5C and D), but not in the mossy
ﬁbre layer of CA3 or in the cerebellar pinceau.
Fourteen sera (10 VGKC-antibody positive; four healthy individ-
uals) were applied to these slices with the observer (K.K.) blind to
their antibody status or clinical syndrome. Six sera (all Lgi1-
antibody positive) bound with similar localization to that of anti-
bodies to Lgi1, whereas two (both Caspr2-antibody positive)
showed strong binding that was similar to that of antibodies to
Caspr2 in both the hippocampus and cerebellum, as well as at the
juxtaparanodes of teased sciatic nerve ﬁbres (Fig. 6 and data not
Figure 5 Expression pattern of Caspr2 and Lgi1 in the CNS. Black and white images of ﬁxed hippocampal (A and B) and cerebellar
(C and D) sections double stained with speciﬁc antibodies to Caspr2 (red), Lgi1 (green) and Kv1.1 (green) as indicated in the merged
images in the right column where cell nuclei are stained with DAPI (blue). In the CA3 area of the hippocampus, Caspr2 (A and B)i s
strongly expressed in the stratum radiatum (rad), whereas Kv1.1 (A) and Lgi1 (B) are most prominent in the mossy ﬁbre layer (mf) where
Caspr2 is almost absent. In the cerebellum, Caspr2 (C and D) is expressed in the molecular (mol) and granule cell layers (GCL), but not in
the pinceau (green arrows) where Kv1.1 (C) as well as Lgi1 (D) are strongly expressed. Scale bar=20mm. pyr=pyramidal cell layer;
PC=Purkinje cell layer.
2742 | Brain 2010: 133; 2734–2748 S. R. Irani et al.Figure 6 Binding patterns of Caspr2 and Lgi1 immunoreactive sera in the CNS. Images of ﬁxed hippocampal (A and B) and cerebellar
(C and D) sections, or sciatic nerve teased ﬁbres (E–G), immunostained with sera (green) from representative patients with limbic
encephalitis/Morvan’s syndrome or healthy controls (far right column in A–D and G) as indicated, combined with speciﬁc antibodies (red)
to Caspr2 (A and C), Lgi1 (B and D) or Caspr (which localizes to the paranode, E–G). For the limbic encephalitis/Morvan’s syndrome, sera
in A–D channels are shown separately as black and white images, as well as merged images to demonstrate reactivity of the sera, while for
the control sera only merged images are shown. Cell nuclei are stained with DAPI (blue). In the CA3 area of the hippocampus Serum 6
(A) binds strongly to the stratum radiatum (rad) where Caspr2 is prominently expressed (A) but not to the mossy ﬁbre layer (mf) where
Caspr2 is almost absent. In contrast, Serum 1 (B) binds to the mf more than the rad, colocalizing with Lgi1. In the cerebellum, Serum 6
(C) colocalizes with Caspr2 in the molecular (mol) and granule cell layers (GCL), but does not bind to the pinceau where Lgi1 is strongly
expressed (red arrows in D) but Caspr2 is absent. In contrast to Serum 6, Serum 1 shows strong binding to the pinceau (green arrows in D)
colocalizing with Lgi1 (insets in D show the pinceau at higher magniﬁcation). Control sera show no speciﬁc binding in CA3 or cerebellum
(A–D). In E–G staining of sciatic nerve teased ﬁbres with antibodies to the paranodal marker Caspr (distinct from Caspr2) and patient
serum, shows that Caspr2-reactive Serum 6 strongly labels the juxtaparanodes that are known to express Caspr2 but not signiﬁcantly Lgi1
(green arrows in E), whereas Lgi1-reactive Serum 1 (F), as well as a control serum (G), shows no speciﬁc binding. Scale bars: A–D=20mm,
E–G=10mm. Serum 1 was from a typical Lgi1-antibody positive limbic encephalitis patient and Serum 6 was from a Caspr2-antibody
positive Morvan’s syndrome patient. Pyr=pyramidal cell layer; PC=Purkinje cell layer.
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1999) but not signiﬁcantly Lgi1 (data not shown). The binding
of the antibodies in Caspr2-immunoreactive sera was abolished
in different neural tissues in Caspr2 knockout mice, including
areas where Caspr2 is dissociated from potassium channel expres-
sion (Supplementary Fig. 2), conﬁrming their speciﬁcity for Caspr2.
The remaining six sera (two VGKC-antibody positive and
four controls) did not show clear localization with either Lgi1 or
Caspr2.
Clinical signiﬁcance of Lgi1 and
Caspr2 antibodies
In Table 3, we compare the clinical features of all the
Lgi1-antibody and Caspr2-antibody patients. Among the 55 pa-
tients with Lgi1-antibodies, 49 developed amnesia, confusion,
neuropsychiatric disturbance and/or seizures typical of limbic en-
cephalitis. Thirty-one had medial temporal lobe high signal on MRI
and 34 had serum hyponatraemia (5135mM). One had epilepsy
only, two had Morvan’s syndrome, only one had isolated neuro-
myotonia and two had other disorders (Supplementary Table 1).
None had active tumours, as determined by whole body MRI/
PET/CT imaging.
By contrast, although around half of the total number of
19 Caspr2-antibody patients had amnesia, confusion and neuro-
psychiatric features, which were very frequent in Lgi1-antibody
positive patients, seizures were less common and many had neu-
romyotonia, neuropathic pain, insomnia, dysautonomia and
weight loss, which were infrequent in Lgi1-antibody patients. All
Figure 7 Clinical scores before and after treatments in patients with Caspr2- or Lgi1-antibodies. (A) Modiﬁed Rankin scores pre- and
post-immunotherapies in patients with Caspr2 antibodies with or without tumours. Many of the patients without tumours improved but
those with tumours often deteriorated, and four died (modiﬁed Rankin scores=6). (B) Modiﬁed Rankin scores in patients with
Lgi1-antibodies before and after immunotherapies. The modiﬁed Rankin scores were signiﬁcantly reduced following treatments. Only one
Lgi1-antibody positive patient died (modiﬁed Rankin scores=6), and their death was unrelated to the clinical syndrome. The Modiﬁed
Rankin Scores (0=asymptomatic patient; 1=symptoms do not interfere with lifestyle; 2=symptoms lead to some restriction of lifestyle
but do not prevent totally independent existence; 3=symptoms signiﬁcantly interfere with lifestyle or prevent totally independent ex-
istence; 4=symptoms clearly prevent independent existence, although patient does not need constant attention day and night; 5=severe
disability, with patient totally dependent and requiring constant attention day and night; 6=death due to the condition) ranges from
0 (normal) to 6 (death) (Graus et al., 2001).
Table 3 Clinical features and diagnoses in patients with
Lgi1 or Caspr2 antibodies
Lgi1
(n=55)
Caspr2
(n=19)
Caspr2
versus Lgi1
(uncorrected
P-values)*
Male:female 37:18 16:3 NS
Amnesia 47 10 0.002
Confusion/disorientation 41 8 0.009
Seizures 49 10 0.0004
MRI medial temporal
lobe high signal
31 5 0.03
Hyponatraemia 34 2 50.0001
Neuromyotonia 2 10 50.0001
Pain 6 7 0.031
Insomnia 4 6 0.017
Other sleep disorder 12 0 0.028
Any dysautonomia 8 6 NS
Active tumour (thymoma) 0 6 (5) 0.0002
Weight loss 2 6 0.003
Death 1 4 0.016
Final diagnosis
Limbic encephalitis 49 7 50.0001
Morvan’s syndrome 2 3 NS
Neuromyotonia only 1 7 0.0002
Epilepsy only 1 2 NS
Other 2 0 NS
Morvan’s syndrome
or neuromyotonia
31 0 50.0001
*The proportions of patients with each antibody who had particular clinical
features were compared by Fishers’ exact test and have not been corrected for
multiple comparisons. NS=not signiﬁcant.
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metrial adenocarcinoma) were in Caspr2-antibody patients. The
differences in the proportions of these features between the two
groups are shown in Table 3, although some would not reach
signiﬁcance after correction for multiple comparisons, due to the
small numbers of Caspr2-antibody positive patients and the diver-
sity of their clinical syndromes.
The patients without detectable antibodies to Lgi1, Caspr2,
contactin-2 or Kv1.2, included seven with limbic encephalitis,
one with epilepsy only, one with neuromyotonia, and nine of
the 12 with undeﬁned neurological syndromes (Supplementary
Table 1).
Response to treatments and outcomes
We used the modiﬁed Rankin scores at the time of diagnosis
and following immunomodulatory therapies to evaluate treatment
responses. Although the treatment schedules and follow-up
times were highly variable, the modiﬁed Rankin scores were
reduced by immunotherapies in the Caspr2-antibody patients,
except in the six with tumours (Fig. 7A), four of whom died
(Table 3). They were substantially reduced in the Lgi1-antibody
patients (Fig. 7B), and only one patient died (from an unrelated
course).
Discussion
VGKC-antibodies deﬁne neurological conditions that are usually
immunotherapy-responsive. As a result, these antibodies have
become part of the investigation of patients with unexplained
subacute onset of epilepsy, memory or cognitive problems, or per-
ipheral nerve hyperexcitability syndromes, but it has been unclear
how the antibodies could cause such a range of different clinical
presentations. Here, we show that the majority of VGKC-
antibodies of high titre are not directed towards the Kv1 subunits
themselves but to two proteins, Lgi1 and Caspr2, that are closely
associated with VGKCs in brain tissue and remain complexed with
the VGKCs in 2% digitonin extracts. Lgi1 antibodies were found
almost exclusively in patients with limbic encephalitis or epilepsy,
all without tumours, whereas antibodies to Caspr2 were found in
patients with limbic encephalitis, Morvan’s syndrome or neuro-
myotonia, often with thymomas. It is interesting that mutations
in genes encoding both these proteins are found in hereditary
epilepsy and other disorders (reviewed by Morante-Redolat
et al., 2002; Kumar and Christian, 2009), reﬂecting the fact that
genetic and autoimmune conditions often target the same
proteins.
An important aim of this work was to study the clinical pheno-
types of the patients in parallel with their antibody speciﬁcities.
We studied 96 patients with high titres of VGKC-antibodies, rep-
resentative of those referred to us for testing. The clinical follow-
ups conﬁrm earlier observations in much smaller studies (Thieben
et al., 2004; Vincent et al., 2004; Graus et al., 2008) that many
VGKC-antibody positive patients (with titres 4400pM) have CNS
disease, that tumours are rare, and that most respond well to
immunotherapies. The majority of the patients (67%) had limbic
encephalitis with typical clinical presentations; the presence of
VGKC-antibodies conﬁrmed this diagnosis in the 41% whose
MRIs were normal (Bien and Elger, 2007). Strikingly, there were
no detectable active tumours in the Lgi1-antibody positive patients
despite a median follow-up of over 3years. Only ﬁve patients
were identiﬁed as having Morvan’s syndrome, illustrating the
rarity of this syndrome; their condition was characterized by
pain, often burning in nature, as well as the typical features of
neuromyotonia, autonomic disturbance and insomnia. Eleven pa-
tients were diagnosed by their neurologists as having neuromyo-
tonia only, but four of these had pain, autonomic dysfunction or
insomnia, features that could be ascribed to Morvan’s syndrome,
suggesting considerable overlap between the two syndromes.
Previous immunohistological data on a small number of high
titre VGKC-antibody positive limbic encephalitis and Morvan’s
syndrome sera suggested co-localization with Kv1.1 or 1.2, or
occasionally Kv1.6 (Buckley et al., 2001; Liguori et al., 2001;
Ances et al., 2005; Antozzi et al., 2005; Kleopa et al., 2006).
Having identiﬁed the true targets for the antibodies in these pa-
tients, it appears that these results were confounded by the very
similar localization of Lgi1 and Kv1.1, particularly in the hippocam-
pus, and of Caspr2 and Kv1.2 (Kv1.2 not shown here but can be
seen in Kleopa et al., 2006), both in the hippocampus and cere-
bellum. Moreover, the precipitation of
125I--DTX-VGKCs with
antibodies to Lgi1 that we show here, conﬁrms earlier experimen-
tal data that the two are closely associated (Schulte et al., 2006).
Whereas Caspr2 is strongly associated with Kv1.1 and Kv1.2 at
juxtaparanodes (Poliak et al., 2003), Lgi1 expression in peripheral
nerves is weak but present (Ogawa et al., 2010; KA Kleopa, un-
published data).
It is important to recognize that the antibodies to Lgi1 and
Caspr2 were ﬁrst measured by binding to the surface of unper-
meabilized cells, and therefore the antibodies are directed towards
‘cell-surface antigens’ on neurons, deﬁning their pathogenic po-
tential (Vincent et al., 2006; Graus et al., 2010), which was sup-
ported by the antibody binding to live hippocampal cultures. At
present we do not have an explanation for the 19% of patients in
whom we could not identify any VGKC-complex antigen; their
lower VGKC-antibody titres (Supplementary Figure 3) suggests
that improvements in our antibody assays may reduce the
number of sera with undeﬁned target antigens. Conversely, it is
highly likely that some patients with limbic encephalitis or
Morvan’s syndrome, previously negative for VGKC antibodies,
will prove to have Lgi1 or Caspr2 antibodies. Further work is
clearly needed.
Lgi1 is an appropriate target for antibodies in limbic encephalitis
and epilepsy, and Lgi1 antibodies have recently been conﬁrmed by
others (Lai et al., 2010). Mutations in Lgi1 are associated with a
distinct form of temporal lobe epilepsy without peripheral nerve
dysfunction (Morante-Redolat et al., 2002). It is notable that 91%
of the Lgi1-antibody positive patients had limbic encephalitis, con-
sistent with Lgi1’s hippocampal localization, and only one had
peripheral symptoms. When we looked for Lgi1 antibodies in
the sera, we were initially confused because the patients’ serum
IgG bound to all of the Lgi1-transfected human embryonic kidney
cells, rather than just to those that were transfected. This was
explained by the fact that Lgi1 is secreted from neurons and
Lgi1 and Caspr2 are targets for VGKC antibodies Brain 2010: 133; 2734–2748 | 2745can then bind to cell surfaces, as shown in neuroblastoma and
COS7 cells (Sirerol-Piquer et al., 2006) and now demonstrated
in HEK293 cells. Lgi1 binds ADAM22 on CNS postsynaptic mem-
branes (Fukata et al., 2006; Ogawa et al., 2010) but we could not
detect ADAM22 in our human embryonic kidney cell cultures
(data not shown); further Lgi1 receptors are being identiﬁed and
might be responsible for our ﬁndings (Sagane et al., 2008). Since,
we were unable to use EGFP-tagged Lgi1 in immunoprecipitation
experiments (data not shown), perhaps because the EGFP-tag
interfered with its conformation, to conﬁrm the target of the
VGKC-antibodies, we expressed Lgi1 fused to the C-terminal
and transmembrane domain of Caspr2; this has provided a more
direct and sensitive method for detection of patients’ antibodies
and will now be developed for routine use. An EGFP construct will
also be made so that the serum antibodies can be quantiﬁed by
immunoprecipitation.
Caspr2 is a more conventional antigenic target. It is a mem-
brane protein with a large extracellular sequence consisting of
multiple well-deﬁned domains (Poliak et al., 1999), and is essential
for the co-localization of Kv1.1 and 1.2 at the juxtaparanodes of
the nodes of Ranvier. Caspr2-knockout mice show dispersed,
non-clustered Kv1 neural expression (Poliak et al., 2003), similar
to that seen in one study of patients with Caspr2-mutations
(Strauss et al., 2006). It is likely that binding of Caspr2 antibodies
results in down-regulation of Caspr2/Kv1.1/1.2 complexes on the
peripheral nerve axon, leading to neuromyotonia, neuropathic
pain and autonomic dysfunction. How these antibodies cause in-
somnia, one of the deﬁning features of Morvan’s syndrome, is not
clear but mutations in CNTNAP2 (which encodes Caspr2) are
associated with epilepsy and cognitive decline as well as peripheral
nerve involvement (Strauss et al., 2006), and have also been
identiﬁed in various forms of schizophrenia, epilepsy and autism
spectrum disorders (reviewed in Kumar and Christian, 2009).
Although in this cohort, only three of the ﬁve patients with
Morvan’s syndrome had Caspr2-antibodies, in a further nine pa-
tients with Morvan’s syndrome and VGKC-antibodies, the majority
had Caspr2-antibodies and six had thymomas (Vincent, 2009 and
unpublished observations); it will be interesting to look for Caspr2
expression in these tumours.
Earlier studies suggested that the Kv1s were the target antigens
in neuromyotonia (Arimura et al., 1997; Hart et al., 1997), but
most of those sera had lower VGKC-antibody titres compared with
those studied here. The targets for sera with lower VGKC antibo-
dies should now be re-explored, but from our initial ﬁndings
(unpublished observations) we anticipate that Kv1s, Caspr2
and contactin-2 will individually, or in combinations, prove to
be targets in many patients with VGKC-antibody positive neuro-
myotonia, and also may be positive in some that are currently
negative for VGKC-antibodies.
In the last few years, antibodies to ion channels and a growing
number of receptors have been identiﬁed in patients with acute or
subacute onset of CNS syndromes (Dalmau and Rosenfeld 2008;
Vincent et al., 2008; Graus et al., 2010). Our results help explain
the diversity of clinical syndromes associated with VGKC-antibodies
and suggest that proteins complexed with these receptors and ion
channels may also prove to be targets for autoantibodies in patients
with these and other autoimmune CNS disorders.
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